marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 10-31-2024
Regeneron Pharmaceuticals Balance Sheet 2011-2024 | REGN
Annual Balance Sheet Regeneron Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-728 M | -1.11 B | -906 M | -215 M | -904 M | -759 M | -109 M | -56.4 M | -562 M | -250 M | -56.9 M | 144 M | -165 M |
Long Term Debt |
1.98 B | 1.98 B | 1.98 B | 1.98 B | - | - | - | - | 10.8 M | 147 M | 320 M | 297 M | 275 M |
Long Term Debt Current |
19 M | 12.4 M | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 1.62 B | 1.53 B | 1.48 B | 1.28 B | 1.14 B | 675 M | 700 M | 672 M | 690 M |
Total Current Liabilities |
3.42 B | 3.14 B | 3.93 B | 2.7 B | 2.1 B | 1.44 B | 1.14 B | 1.24 B | 811 M | 655 M | 299 M | 164 M | 148 M |
Total Liabilities |
7.11 B | 6.55 B | 6.67 B | 6.14 B | 3.72 B | 2.98 B | 2.62 B | 2.52 B | 1.95 B | 1.33 B | 999 M | 835 M | 838 M |
Deferred Revenue |
459 M | 478 M | 442 M | 341 M | 592 M | 452 M | 320 M | 232 M | 153 M | 74 M | 47 M | 50.8 M | 51.6 M |
Retained Earnings |
27.3 B | 23.3 B | 19 B | 10.9 B | 7.38 B | 5.25 B | 2.95 B | 1.75 B | 853 M | 255 M | -92.7 M | -517 M | -1.27 B |
Total Assets |
33.1 B | 29.2 B | 25.4 B | 17.2 B | 14.8 B | 11.7 B | 8.76 B | 6.97 B | 5.61 B | 3.87 B | 2.95 B | 2.08 B | 1.32 B |
Cash and Cash Equivalents |
2.73 B | 3.11 B | 2.89 B | 2.19 B | 1.62 B | 1.47 B | 813 M | 535 M | 809 M | 649 M | 536 M | 230 M | 484 M |
Book Value |
26 B | 22.7 B | 18.8 B | 11 B | 11.1 B | 8.76 B | 6.14 B | 4.45 B | 3.65 B | 2.54 B | 1.95 B | 1.25 B | 486 M |
Total Shareholders Equity |
26 B | 22.7 B | 18.8 B | 11 B | 11.1 B | 8.76 B | 6.14 B | 4.45 B | 3.65 B | 2.55 B | 1.96 B | 1.25 B | 486 M |
All numbers in USD currency
Quarterly Balance Sheet Regeneron Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
1.98 B | 1.98 B | 1.98 B | 1.98 B | 1.98 B | 1.98 B | 1.98 B | 1.98 B | - | 1.98 B | 1.98 B | 1.98 B | 1.98 B | 1.98 B | 1.98 B | 1.98 B | 1.98 B | 1.98 B | - | - | 714 M | 714 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
8.12 B | 7.88 B | 7.38 B | 7.26 B | 6.64 B | 6.56 B | 6.55 B | 6.24 B | - | 6.43 B | 6.67 B | 6.41 B | 6.36 B | 5.8 B | 6.14 B | 6.14 B | 6.14 B | 6.14 B | 3.72 B | 3.72 B | 3.72 B | 3.72 B | 2.98 B | 2.98 B | 2.98 B | 2.98 B | 2.62 B | 2.62 B | 2.62 B | 2.62 B | 2.52 B | 2.52 B | 2.52 B | 2.52 B | 1.95 B | 1.95 B | 1.95 B | 1.95 B | 1.29 B | 1.29 B | 1.29 B | 1.33 B | 999 M | 999 M | 999 M | 999 M | 835 M | 835 M | 835 M | 835 M | 838 M | 838 M | 838 M | 838 M |
Deferred Revenue |
627 M | 586 M | 517 M | 417 M | 381 M | 426 M | 478 M | 547 M | - | 491 M | 442 M | 508 M | 520 M | 465 M | 578 M | 578 M | 578 M | 578 M | 592 M | - | - | - | 452 M | - | - | 160 M | 142 M | 133 M | 128 M | 126 M | 232 M | 116 M | 116 M | 116 M | 153 M | 51.9 M | 51.9 M | 51.9 M | 74 M | 58.1 M | 58.1 M | 58.1 M | 47 M | 34.2 M | 34.2 M | 34.2 M | 50.8 M | 33.8 M | 33.8 M | 33.8 M | 51.6 M | 31.6 M | 33.6 M | 33.3 M |
Retained Earnings |
30.8 B | 29.4 B | 28 B | 26.1 B | 25.1 B | 24.1 B | 23.3 B | 22.1 B | - | 19.9 B | 19 B | 16.7 B | 15.1 B | 12 B | 10.9 B | 10.9 B | 10.9 B | 10.9 B | 7.38 B | 7.38 B | 7.38 B | 7.38 B | 5.25 B | 5.25 B | 5.25 B | 5.25 B | 2.95 B | 2.95 B | 2.95 B | 2.95 B | 1.75 B | 1.75 B | 1.75 B | 1.75 B | 853 M | 853 M | 853 M | 853 M | 217 M | 217 M | 217 M | 217 M | -92.7 M | -92.7 M | -92.7 M | -92.7 M | -517 M | -517 M | -517 M | -517 M | -1.27 B | -1.27 B | -1.27 B | -1.27 B |
Total Assets |
37.4 B | 36.1 B | 34.4 B | 32.2 B | 30.7 B | 30.1 B | 29.2 B | 27.7 B | - | 26.3 B | 25.4 B | 23.7 B | 21.5 B | 17.8 B | 17.2 B | 17.2 B | 17.2 B | 17.2 B | 14.8 B | 14.8 B | 14.8 B | 14.8 B | 11.7 B | 11.7 B | 11.7 B | 11.7 B | 8.76 B | 8.76 B | 8.76 B | 8.76 B | 6.97 B | 6.97 B | 6.97 B | 6.97 B | 5.61 B | 5.61 B | 5.61 B | 5.61 B | 3.84 B | 3.84 B | 3.84 B | 3.89 B | 2.95 B | 2.95 B | 2.95 B | 2.95 B | 2.08 B | 2.08 B | 2.08 B | 2.08 B | 1.32 B | 1.32 B | 1.32 B | 1.32 B |
Cash and Cash Equivalents |
2.01 B | 1.92 B | 2.6 B | 2.15 B | 1.94 B | 3.92 B | 3.11 B | 3.49 B | 3.4 B | 3.35 B | 2.89 B | 3.43 B | 2.07 B | 1.44 B | 2.19 B | 2.19 B | 2.19 B | 2.19 B | 1.62 B | 1.62 B | 1.62 B | 1.62 B | 1.47 B | 1.47 B | 1.47 B | 1.47 B | 813 M | 813 M | 813 M | 813 M | 535 M | 535 M | 535 M | 535 M | 809 M | 809 M | 809 M | 809 M | 649 M | 649 M | 649 M | 649 M | 536 M | 536 M | 536 M | 536 M | 230 M | 230 M | 230 M | 230 M | 484 M | 484 M | 484 M | 484 M |
Book Value |
29.3 B | 28.2 B | 27 B | 24.9 B | 24 B | 23.5 B | 22.7 B | 21.4 B | - | 19.9 B | 18.8 B | 17.3 B | 15.1 B | 12 B | 11 B | 11 B | 11 B | 11 B | 11.1 B | 11.1 B | 11.1 B | 11.1 B | 8.76 B | 8.76 B | 8.76 B | 8.76 B | 6.14 B | 6.14 B | 6.14 B | 6.14 B | 4.45 B | 4.45 B | 4.45 B | 4.45 B | 3.65 B | 3.65 B | 3.65 B | 3.65 B | 2.55 B | 2.55 B | 2.55 B | 2.56 B | 1.95 B | 1.95 B | 1.95 B | 1.95 B | 1.25 B | 1.25 B | 1.25 B | 1.25 B | 486 M | 486 M | 486 M | 486 M |
Total Shareholders Equity |
29.3 B | 28.2 B | 27 B | 24.9 B | 24 B | 23.5 B | 22.7 B | 21.4 B | 20.7 B | 19.9 B | 18.8 B | 17.3 B | 15.1 B | 12 B | 11 B | 11 B | 11 B | 11 B | 11.1 B | 11.1 B | 11.1 B | 11.1 B | 8.76 B | 8.76 B | 8.76 B | 8.76 B | 6.14 B | 6.14 B | 6.14 B | 6.14 B | 4.45 B | 4.45 B | 4.45 B | 4.45 B | 3.65 B | 3.65 B | 3.65 B | 3.65 B | 2.55 B | 2.55 B | 2.55 B | 2.56 B | 1.96 B | 1.95 B | 1.95 B | 1.95 B | 1.26 B | 1.25 B | 1.25 B | 1.25 B | 486 M | 486 M | 486 M | 486 M |
All numbers in USD currency